Skip to main content
ACS AuthorChoice logoLink to ACS AuthorChoice
. 2022 Oct 3;65(19):13482. doi: 10.1021/acs.jmedchem.2c01533

Correction to “Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction”

Tord Inghardt , Thomas Antonsson, Cecilia Ericsson, Daniel Hovdal, Petra Johannesson, Carina Johansson, Ulrik Jurva , Johan Kajanus, Bengt Kull, Erik Michaëlsson, Anna Pettersen, Tove Sjögren, Henrik Sörensen, Kristina Westerlund, Eva-Lotte Lindstedt
PMCID: PMC9574857  PMID: 36190771

An incorrect Supporting Information PDF file was uploaded with the published article. The correct file for this paper is provided here.

Supporting Information Available

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c01533.

  • Synthesis procedures, drug metabolism and pharmacokinetic assays, and tables with data including statistics; NMR spectra, vibrational circular dichroism spectra, and enantiomeric excess, and HPLC traces (PDF)

Supplementary Material

jm2c01533_si_001.pdf (4.4MB, pdf)

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

jm2c01533_si_001.pdf (4.4MB, pdf)

Articles from Journal of Medicinal Chemistry are provided here courtesy of American Chemical Society

RESOURCES